The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2022 | Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLC
Byoung Chul Cho, MD, PhD , Yonsei University College of Medicine in Seoul, Republic of Korea, shares updated results of the Phase I CHRYSALIS study (NCT02609776) evaluating the combination of amivantamab and lazertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC). As previously reported, all 20 patients in the treatment-naïve cohort achieved a partial response (PR) after a median follow-up of 7 months. At a median follow-up of 22.3 months, the median duration of response (DoR) and median progression-free survival (PFS) were not reached. At the time of data cutoff, 70% of patients were progression-free and remain on therapy. Baseline ctDNA analysis was performed on 18 patients, 15 of which had detectable EGFR activating mutations. Following treatment, activating EGFR mutations were not detected in any of the 15 patients with baseline positive ctDNA. There is now an ongoing Phase III MARIPOSA study (NCT04487080) is investigating amivantamab and lazertinib versus as front-lien therapy for EGFR-mutated NSCLC. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
